Literature DB >> 29229670

Kras and Tumor Immunity: Friend or Foe?

Jane Cullis1, Shipra Das1, Dafna Bar-Sagi1.   

Abstract

With the recent breakthroughs in immunotherapy as curative treatments in certain tumor types, there has been renewed interest in the relationship between immunity and tumor growth. Although we are gaining a greater understanding of the complex interplay of immune modulating components in the tumor microenvironment, the specific role that tumor cells play in shaping the immune milieu is still not well characterized. In this review, we focus on how mutant Kras tumor cells contribute to tumor immunity, with a specific focus on processes induced directly or indirectly by the oncogene.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29229670      PMCID: PMC6120695          DOI: 10.1101/cshperspect.a031849

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  155 in total

1.  Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.

Authors:  Kyoung Eun Lee; Michelle Spata; Lauren J Bayne; Elizabeth L Buza; Amy C Durham; David Allman; Robert H Vonderheide; M Celeste Simon
Journal:  Cancer Discov       Date:  2015-12-29       Impact factor: 39.397

2.  Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation.

Authors:  T S Finco; J K Westwick; J L Norris; A A Beg; C J Der; A S Baldwin
Journal:  J Biol Chem       Date:  1997-09-26       Impact factor: 5.157

3.  Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Authors:  Zhong-Yi Dong; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Zhi Xie; Si-Yang Liu; Hai-Yan Tu; Hua-Jun Chen; Yue-Li Sun; Qing Zhou; Jin-Ji Yang; Xue-Ning Yang; Jia-Xin Lin; Hong-Hong Yan; Hao-Ran Zhai; Li-Xu Yan; Ri-Qiang Liao; Si-Pei Wu; Yi-Long Wu
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

4.  High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer.

Authors:  Dong Tang; Zhongxu Yuan; Xiaofeng Xue; Zipeng Lu; Ye Zhang; Hui Wang; Minyong Chen; Yong An; Jishu Wei; Yi Zhu; Yi Miao; Kuirong Jiang
Journal:  Int J Cancer       Date:  2011-11-28       Impact factor: 7.396

5.  Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.

Authors:  Jeremy J W Chen; Pei-Li Yao; Ang Yuan; Tse-Ming Hong; Chia-Tung Shun; Min-Liang Kuo; Yung-Chie Lee; Pan-Chyr Yang
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

6.  Constitutive activation of NF-kappaB in Ki-ras-transformed prostate epithelial cells.

Authors:  Bo-Yeon Kim; Richard B Gaynor; Kyung Song; Anatoly Dritschilo; Mira Jung
Journal:  Oncogene       Date:  2002-07-04       Impact factor: 9.867

Review 7.  Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.

Authors:  Véronique Baud; Michael Karin
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

Review 8.  Targeting cytotoxic T lymphocytes for cancer immunotherapy.

Authors:  J Maher; E T Davies
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

9.  Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs.

Authors:  Geou-Yarh Liou; Heike Döppler; Brian Necela; Murli Krishna; Howard C Crawford; Massimo Raimondo; Peter Storz
Journal:  J Cell Biol       Date:  2013-08-05       Impact factor: 10.539

10.  CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Authors:  Colin W Steele; Saadia A Karim; Joshua D G Leach; Peter Bailey; Rosanna Upstill-Goddard; Loveena Rishi; Mona Foth; Sheila Bryson; Karen McDaid; Zena Wilson; Catherine Eberlein; Juliana B Candido; Mairi Clarke; Colin Nixon; John Connelly; Nigel Jamieson; C Ross Carter; Frances Balkwill; David K Chang; T R Jeffry Evans; Douglas Strathdee; Andrew V Biankin; Robert J B Nibbs; Simon T Barry; Owen J Sansom; Jennifer P Morton
Journal:  Cancer Cell       Date:  2016-06-02       Impact factor: 38.585

View more
  28 in total

Review 1.  Genomic correlates of response to immune checkpoint blockade.

Authors:  Tanya E Keenan; Kelly P Burke; Eliezer M Van Allen
Journal:  Nat Med       Date:  2019-03-06       Impact factor: 53.440

2.  Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.

Authors:  Shipra Das; Beny Shapiro; Emily A Vucic; Sandra Vogt; Dafna Bar-Sagi
Journal:  Cancer Res       Date:  2020-01-08       Impact factor: 12.701

Review 3.  The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.

Authors:  Alessia Spagnuolo; Paolo Maione; Cesare Gridelli
Journal:  Transl Lung Cancer Res       Date:  2022-06

4.  Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

Authors:  Edurne Mugarza; Febe van Maldegem; Jesse Boumelha; Christopher Moore; Sareena Rana; Miriam Llorian Sopena; Philip East; Rachel Ambler; Panayiotis Anastasiou; Pablo Romero-Clavijo; Karishma Valand; Megan Cole; Miriam Molina-Arcas; Julian Downward
Journal:  Sci Adv       Date:  2022-07-20       Impact factor: 14.957

5.  KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.

Authors:  Yoshihisa Tokumaru; Masanori Oshi; Eriko Katsuta; Li Yan; Vikas Satyananda; Nobuhisa Matsuhashi; Manabu Futamura; Yukihiro Akao; Kazuhiro Yoshida; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 6.  Macropinocytosis as a cell entry route for peptide-functionalized and bystander nanoparticles.

Authors:  Yue-Xuan Li; Hong-Bo Pang
Journal:  J Control Release       Date:  2020-10-24       Impact factor: 9.776

7.  Construction of an immune-related signature with prognostic value for colon cancer.

Authors:  Yunxia Lv; Xinyi Wang; Yu Ren; Xiaorui Fu; Taiyuan Li; Qunguang Jiang
Journal:  PeerJ       Date:  2021-05-05       Impact factor: 2.984

Review 8.  Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer.

Authors:  Emily K Kleczko; Jeff W Kwak; Erin L Schenk; Raphael A Nemenoff
Journal:  Front Immunol       Date:  2019-05-10       Impact factor: 7.561

9.  FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma.

Authors:  Kai Yuan; Yanyan Feng; Hesong Wang; Lu Zhao; Wei Wang; Ting Wang; Yuyin Feng; Guangrui Huang; Anlong Xu
Journal:  PeerJ       Date:  2020-03-13       Impact factor: 2.984

10.  Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq.

Authors:  Hongkai Zhuang; Xinming Chen; Ying Wang; Shanzhou Huang; Bo Chen; Chuanzhao Zhang; Baohua Hou
Journal:  Cancer Immunol Immunother       Date:  2021-07-19       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.